A Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal™) to Provide Symptomatic Relief of Osteoarthritis of the Knee

Trial Profile

A Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal™) to Provide Symptomatic Relief of Osteoarthritis of the Knee

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Hyaluronic acid/triamcinolone (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Anika Therapeutics
  • Most Recent Events

    • 26 Jul 2017 According to an Anika Therapeutics media release, approximately 30 patients have been enrolled to date, and the company expects to complete patient enrollment by the end of 2017.
    • 30 May 2017 According to an Anika Therapeutics media release, data from this trial will be presented at the 2017 European Federation of National Associations of Orthopedics and Traumatology (EFORT) Annual Congress.
    • 25 May 2017 According to an Anika Therapeutics media release, the company expects to complete this trial in 2018 and anticipates US FDA approval in the following year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top